Truist lowered the firm’s price target on Insulet (PODD) to $360 from $390 and keeps a Buy rating on the shares. The company posted another strong Q4 beat on broad worldwide Omnipod 5 strength as it continues to expand on its first-mover advantage in T2D, leveraging investments in its DTC marketing strategy to accelerate new patient starts, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PODD:
- Insulet price target lowered to $340 from $370 at Evercore ISI
- Insulet price target lowered to $326 from $363 at Goldman Sachs
- Insulet price target lowered to $300 from $365 at Oppenheimer
- Insulet price target lowered to $340 from $415 at JPMorgan
- Insulet price target lowered to $330 from $380 at Bernstein